Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations

被引：0

作者：

Solomon, B. J. ^{[1
]}

Martini, J-F. ^{[2
]}

Ou, S-H. I. ^{[3
]}

Chiari, R. ^{[4
]}

Soo, R. A. ^{[5
]}

Bearz, A. ^{[6
]}

Li, S. ^{[2
]}

Thurm, H. ^{[2
]}

Lin, C-C. ^{[7
]}

Riely, G. J. ^{[8
]}

Bauer, T. M. ^{[9
]}

Shaw, A. T. ^{[10
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Pfizer Oncol, La Jolla, CA USA

[3] Univ Calif Irvine, Med Ctr, Chao Family Comprehens Canc Ctr, Irvine, CA USA

[4] Azienda Osped Perugia, Perugia, Italy

[5] Natl Univ Canc Inst, Singapore, Singapore

[6] Natl Inst Canc Res, Aviano, Italy

[7] Natl Taiwan Univ Hosp, Taipei, Taiwan

[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[9] Sarah Cannon Canc Res Inst Tennessee Oncol, Nashville, TN USA

[10] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1380PD

引用

页码：495 / 495

页数：1